Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bolland

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey, Mark Bolland, Greg Gamble, et al.
European Journal of Endocrinology|November 13, 2013
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trialAndrew Grey, Mark Bolland, Sheryl Fenwick, et al.
BMJ (Clinical Research Ed.)|November 16, 2017
Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysisChenhan Ma, Alison Avenell, Mark Bolland, et al.
The Journal of Clinical Endocrinology and Metabolism|July 7, 2005
Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trialIan R Reid, Jenny Lucas, Diana Wattie, et al.
The Journal of Clinical Endocrinology and Metabolism|April 5, 2013
Low-dose fluoride in postmenopausal women: a randomized controlled trialAndrew Grey, Sanjay Garg, Michael Dray, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2016
Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort studyRichard N Clayton, Peter W Jones, Raoul C Reulen, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
The Journal of Clinical Endocrinology and Metabolism|February 1, 2007
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialAndrew Grey, Mark Bolland, Greg Gamble, et al.
European Journal of Endocrinology|November 13, 2013
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trialAndrew Grey, Mark Bolland, Sheryl Fenwick, et al.
BMJ (Clinical Research Ed.)|November 16, 2017
Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysisChenhan Ma, Alison Avenell, Mark Bolland, et al.
The Journal of Clinical Endocrinology and Metabolism|July 7, 2005
Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trialIan R Reid, Jenny Lucas, Diana Wattie, et al.
The Journal of Clinical Endocrinology and Metabolism|April 5, 2013
Low-dose fluoride in postmenopausal women: a randomized controlled trialAndrew Grey, Sanjay Garg, Michael Dray, et al.
The Lancet. Diabetes & Endocrinology|June 7, 2016
Mortality in patients with Cushing's disease more than 10 years after remission: a multicentre, multinational, retrospective cohort studyRichard N Clayton, Peter W Jones, Raoul C Reulen, et al.
Pageof 5